YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer.

ABSTRACT:

Background

Despite the availability of several treatments for non-muscle-invasive bladder cancer (NMIBC), many patients are still not responsive to treatments, and the disease progresses. A new prognostic classifier can differentiate between treatment response and progression, and it could be used as a very important tool in patient decision-making regarding treatment options. In this study, we focused on the activation of Yes-associated protein 1 (YAP1), which is known to play a pivotal role in tumour progression and serves as a factor contributing to the mechanism of resistance to various relevant therapeutic agents. We further evaluated its potential as a novel prognostic agent.

Methods

We identified YAP1-associated gene signatures based on UC3-siYAP1 cells (n=8) and NMIB

SUBMITTER: Baek SW 

PROVIDER: S-EPMC9166372 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature